Lexaria Technology Shows Promise In Improving Performance Of ED Drugs

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

  • Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease 
  • Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”)
  • The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation”
  • ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025

Lexaria Bioscience LEXX, a global innovator in drug delivery platforms, has made a case for increasing the rapidity and effectiveness of medication absorption through Lexaria’s patented DehydraTECH(TM) technology. Recent clinical studies have shown the potential for improved bio-effectiveness of nicotine and cannabidiol (“CBD”) when processed with DehydraTECH for the potential treatment of conditions such as high blood pressure and arterial stiffness, for example. 

In a Feb. 2 news release, the company announced it has also observed successes when administering…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Image sourced from Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksGeneralInvestorBrandNetworkPartner Content
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!